prucalopride sold brand names resolor motegrity among others medication acting selective high affinity receptor targets impaired motility associated chronic constipation thus normalizing bowel prucalopride approved medical use european union canada israel united states december drug also tested treatment chronic intestinal primary measure efficacy clinical trials three spontaneous complete bowel movements per week secondary measure increase least one complete spontaneous bowel movement per measures improvements quality life measure range stool abdominal rectal symptoms associated chronic constipation infrequent bowel movements bloating straining abdominal pain defecation urge inability evacuate severe symptoms significantly affecting quality three large clinical trials weeks treatment prucalopride mgday resulted significantly higher proportion patients reaching primary efficacy endpoint average spontaneous complete bowel movements also significantly improved bowel habit associated symptoms patient satisfaction bowel habit treatment hrqol patients severe chronic constipation including experience adequate relief prior therapies trial improvement patient satisfaction bowel habit treatment maintained treatment months prucalopride therapy generally well small clinical trials suggested prucalopride administration results receptor agonismassociated memory enhancing healthy participants improving ability recall increasing neural activation hippocampus functionally related prucalopride contraindicated hypersensitivity active substance excipients renal impairment requiring dialysis intestinal perforation obstruction due structural functional disorder gut wall obstructive ileus severe inflammatory conditions intestinal tract crohns disease ulcerative colitis toxic prucalopride given orally patients chronic constipation controlled clinical trials frequently reported side effects headache gastrointestinal symptoms abdominal pain nausea diarrhea reactions occur predominantly start therapy usually disappear within days continued prucalopride first class dihydrobenzofurancarboxamide selective high affinity serotonin receptor agonist enterokinetic prucalopride alters colonic motility patterns via serotonin receptor stimulation stimulates colonic mass movements provide main propulsive force defecation observed effects exerted via highly selective action prucalopride higher affinity receptors prucalopride differs agonists tegaserod cisapride therapeutic concentrations also interact receptors cardiac human etheragogo k herg channel respectively may account adverse cardiovascular events resulted restricted availability clinical trials evaluating effect prucalopride qt interval related adverse events demonstrated significant differences compared prucalopride rapidly absorbed cmax attained hours single mg oral dose extensively distributed metabolism major route elimination vitro human liver metabolism slow minor amounts metabolites found large fraction active substance excreted unchanged administered dose urine least feces renal excretion unchanged prucalopride involves passive filtration active secretion plasma clearance averages mlmin terminal halflife steadystate reached within days daily treatment mg prucalopride steadystate plasma concentrations fluctuate trough peak values ngml vitro data indicate prucalopride low interaction potential therapeutic concentrations prucalopride expected affect cypmediated metabolism comedicated medicinal european economic area prucalopride originally approved symptomatic treatment chronic constipation women laxatives fail provide adequate subsequently approved european commission use adults including male patients httpsenwikipediaorgwikiprucalopride